- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03995173
Pilot rTMS for AUD+mTBI (TMS_AUD+mTBI)
January 3, 2024 updated by: VA Office of Research and Development
Brain Targets for Alcohol Craving in Veterans With mTBI
This is a pilot randomized controlled trial (RCT) for Veteran participants with alcohol use disorder co-occurring with mild traumatic brain injury and/or post-traumatic stress disorder.
The treatment intervention is repetitive Transcranial Magnetic Stimulation (rTMS) and the goal is to reduce alcohol craving with this treatment.
The study will enroll 20 Veteran participants.
Half of these participants will receive real rTMS and half of the participants will receive placebo rTMS.
rTMS treatment will be provided over 10 sessions that will occur once every weekday for 2 weeks.
Veteran participants will then complete follow-up phone calls to further evaluate alcohol craving and other symptoms.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
Mild traumatic brain injury (mTBI), post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) are high priority disorders for the Department of Veterans Affairs (VA), in part, because these disorders rarely occur in isolation.
The co-occurrence compounds brain impairment and negatively impacts symptom presentation and rehabilitation effectiveness.
Veterans with co-occurring AUD, mTBI and/or PTSD have few effective treatment options.
Thus, treatment development for these Veterans is of great need.
The aim of this protocol is to examine safety, feasibility, and the behavioral and neural effects of an repetitive transcranial magnetic stimulation (rTMS) intervention for Veterans with AUD and co-occurring mTBI and/or PTSD.
Behavioral and neural effects of rTMS will be examined after the first rTMS session and after the last rTMS session.
The investigators hypothesize that the rTMS intervention will be 1) safe, 2) feasible and 3) efficacious.
Specifically, the investigators hypothesize that there will be no adverse events related to the rTMS intervention.
The investigators hypothesize that all participants enrolled will successfully complete all rTMS sessions.
The investigators hypothesize that participants treated with active rTMS, relative to placebo rTMS, will have reduced alcohol craving severity levels.
Finally, the investigators hypothesize that participants treated with active rTMS relative to placebo rTMS will have reduced brain activation in response to alcohol cues and improved functional connectivity after the last rTMS session.
This is a prospective, pilot, double-blind randomized controlled trial of the intervention rTMS.
There will be 2 groups of Veterans with AUD and co-occurring mTBI and/or PTSD those given 1) active rTMS and those given 2) placebo rTMS.
Targeted enrollment for this study is 20 Veterans: n=10 active rTMS and n=10 placebo rTMS.
Participants will be screened for safety and evaluated on mental health-related behavioral measures.
Eligible participants will be randomized to receive active or placebo rTMS.
Participants will then complete motor thresholding (MT) to determine rTMS intensity.
Participants will then complete 10 sessions of rTMS.
These sessions will be completed once daily on week days over two weeks.
TMS pulses will be applied to the left DLPFC at 10Hz rate, 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session.
After the 10th rTMS session, participants will complete an MRI which will last approximately 1hour.
A sub-sample of participants will complete an MRI immediately after the first rTMS session.
Participants will also repeat the mental health behavioral measures after the last rTMS session.
Participants will complete follow-up phone interviews to assess for alcohol craving, mTBI symptoms and PTSD symptoms at one day, one week and one month post-rTMS.
Completion of this study is an essential first step towards treatment development for Veterans with co-occurring AUD, mTBI and/or PTSD.
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Hines, Illinois, United States, 60141-3030
- Edward Hines Jr. VA Hospital, Hines, IL
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
22 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- English Speaking
- Veterans
- Ages 22 through 65
- Meeting AUDIT-C criteria for AUD (4 for men and 3 for women)
- Pass MRI screening using the Center for Translational Imaging (CTI) Safety Form.
- Clinical Institute of Withdrawal Assessment in Alcohol Withdrawal (CIWA-Ar) scores of 10
Exclusion Criteria:
- History of moderate to severe TBI
- Documented and verified history of psychotic spectrum disorders (i.e., schizophrenia, bipolar)
- Receipt of anti-epileptic medications to control active seizures or evidence of documented seizure within past six months
- Receipt of tricyclic anti-depressants, antipsychotic agents, or other drugs that lower the seizure threshold
Current use of:
- opiates
- cocaine
- amphetamines
- barbiturates
- benzodiazepine
- marijuana/cannabis dependence as determined by the SCID-IV
Currently prescribed any anti-craving/addiction medications, i.e.:
- naltrexone
- varenicline
- bupropion
- disulfiram
- acamprosate
- Meet questionable validity or malingering criteria on the Minnesota Multiphasic Personality Inventory-2-RF (MMPI-2-RF; F: T score 107; F(p): T score 85; TRIN: T score 80; VRIN: T score 80) or the Letter Memory Test (LMT; total score 92%), as determined in IRB#13-077
- Pregnant or nursing
- Have congestive heart failure
Have cardiac pacemaker or defibrillator, or:
- cochlear implant
- nerve stimulator
- intracranial metal clips
- implanted medical pump
- increased intracranial pressure
History of:
- surgery on blood vessels in brain and/or valves of the heart
- brain hemorrhage
- neurovascular conditions
- neurodegenerative disorders
- claustrophobia
- metal in eye/face
- shrapnel/bullet remnants in brain
- Actively suicidal as evidenced by plan to harm or recent attempt communicated on the BDI-II or electronic medical record within the past 6 months
- History of mild TBI within the last 3 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: active
active rTMS
|
rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P.
The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
Other Names:
|
Placebo Comparator: placebo
placebo rTMS
|
rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P.
The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Penn Alcohol Craving Scale Change
Time Frame: baseline, immediately after last/10th rTMS session, and 1 day, 1 week, and 1 month follow-up
|
5-item self-report measure of alcohol craving and each item is scored on a scale of 0 to 6.
The minimum total score is 0 and the maximum is 30, indicating less to more severe alcohol craving, respectively.
|
baseline, immediately after last/10th rTMS session, and 1 day, 1 week, and 1 month follow-up
|
Total Adverse Event Frequency
Time Frame: immediately after last/10th rTMS session - up to 2 weeks
|
An adverse event log will be kept for each participant and each rTMS treatment session.
After each treatment these events will be recorded and the total frequency of events will be used as the outcome after all 10 rTMS sessions over the course of the 2 week treatment have been completed.
|
immediately after last/10th rTMS session - up to 2 weeks
|
Total rTMS Sessions Completed
Time Frame: after the 10th and last rTMS treatment session - up to 2 weeks
|
Total number of rTMS treatment sessions completed out of 10 sessions.
After all 10 rTMS sessions over the course of the 2 week treatment this cumulative total number of sessions complete can be computed.
|
after the 10th and last rTMS treatment session - up to 2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Amy A Herrold, PhD BA, Edward Hines Jr. VA Hospital, Hines, IL
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 21, 2019
Primary Completion (Estimated)
November 22, 2024
Study Completion (Estimated)
November 22, 2024
Study Registration Dates
First Submitted
April 16, 2019
First Submitted That Met QC Criteria
June 19, 2019
First Posted (Actual)
June 21, 2019
Study Record Updates
Last Update Posted (Actual)
January 5, 2024
Last Update Submitted That Met QC Criteria
January 3, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Alcohol-Related Disorders
- Substance-Related Disorders
- Wounds and Injuries
- Craniocerebral Trauma
- Trauma, Nervous System
- Trauma and Stressor Related Disorders
- Head Injuries, Closed
- Wounds, Nonpenetrating
- Alcoholism
- Brain Injuries
- Stress Disorders, Traumatic
- Stress Disorders, Post-Traumatic
- Brain Injuries, Traumatic
- Brain Concussion
Other Study ID Numbers
- B0949-W
- IK2RX000949 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use Disorder
-
Washington State UniversityRecruitingNicotine Use Disorder | Alcohol Use Disorder (AUD)United States
-
University of North Carolina, Chapel HillCompletedAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateUnited States
-
Université du Québec à Trois-RivièresCompletedAlcohol Use, Unspecified | Alcohol Use Disorder, MildCanada
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Medical University of South CarolinaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes...RecruitingAlcohol Drinking | Substance Use | Alcohol Use Disorder | Drinking, Alcohol | Alcohol Use Disorder (AUD)United States
-
Kaiser PermanenteNORC at the University of Chicago; Agency for Healthcare Research and Quality... and other collaboratorsCompleted
-
ITAB - Institute for Advanced Biomedical TechnologiesNot yet recruitingNeurobiological Effects of Transcranial Direct Current Stimulation Treatment in Alcohol Use DisorderAlcohol Dependence | Alcohol-Related Disorders | Substance Use Disorders | Drug Abuse | Mental Disorder | Alcohol Abuse | Alcohol Use Disorder (AUD)
-
University Hospital, Basel, SwitzerlandSolidarMedRecruitingAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateLesotho
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Central Institute of Mental Health, MannheimNot yet recruitingAlcohol Use Disorder (AUD)Germany
Clinical Trials on repetitive transcranial magnetic stimulation
-
State University of New York - Upstate Medical...RecruitingHeadache | Brain Concussion | Mild Traumatic Brain Injury | Post-Concussion SymptomsUnited States
-
Xuzhou Central HospitalThe Affiliated Hospital of Xuzhou Medical UniversityNot yet recruitingFunctional Magnetic Resonance Imaging | Executive Function Disorder
-
Al-Azhar UniversityCompleted
-
Guangzhou Psychiatric HospitalCompletedCognitive Impairment | Bipolar Disorder | RelapseChina
-
Fatih Sultan Mehmet Training and Research HospitalCompletedFailed Back Surgery Syndrome
-
Veterans Medical Research FoundationUnited States Department of DefenseCompletedHeadache | Gulf War SyndromeUnited States
-
Yi YangRecruitingTranscranial Magnetic StimulationChina
-
Yi YangRecruitingTranscranial Magnetic StimulationChina
-
First Affiliated Hospital of Zhejiang UniversityCompletedBipolar DisorderChina
-
Izmir Katip Celebi UniversityCompletedPost-stroke Shoulder PainTurkey